Krishnaswamy Yeleswaram net worth and biography

Krishnaswamy Yeleswaram Biography and Net Worth

Insider of Rapport Therapeutics

Prior to joining Rapport, Swamy was a founding scientist at Incyte, where he held positions of increasing responsibility for 20 years. He was most recently Group Vice President of Drug Metabolism, Pharmacokinetics, and Clinical Pharmacology. Swamy was a key contributor to the discovery and development of Jakafi®, Pemazyre® & Opzelura®. He is a co-inventor on multiple patents and has published extensively on Incyte pipeline products. Prior to Incyte, Swamy held positions at DuPont Pharmaceuticals and at Bristol-Myers Squibb. Swamy received his bachelor’s degree in Pharmacy from Madras Medical College and his master’s degree in Pharmaceutical Sciences from Banaras Hindu University. He received his Ph.D. in Pharmaceutical Sciences from the University of British Columbia.

What is Krishnaswamy Yeleswaram's net worth?: The estimated net worth of Krishnaswamy Yeleswaram is at least $8.09 million as of December 31st, 2025. Yeleswaram owns 296,991 shares of Rapport Therapeutics stock worth more than $8,091,520 as of February 6th. This net worth evaluation does not reflect any other investments that Yeleswaram may own. Learn More about Krishnaswamy Yeleswaram's net worth.
How do I contact Krishnaswamy Yeleswaram?: The corporate mailing address for Yeleswaram and other Rapport Therapeutics executives is , , . Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on Krishnaswamy Yeleswaram's contact information.
Has Krishnaswamy Yeleswaram been buying or selling shares of Rapport Therapeutics?: Krishnaswamy Yeleswaram has not been actively trading shares of Rapport Therapeutics within the last three months. Most recently, Krishnaswamy Yeleswaram sold 2,840 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a transaction totalling $85,342.00. Following the completion of the sale, the insider now directly owns 296,991 shares of the company's stock, valued at $8,924,579.55. Learn More on Krishnaswamy Yeleswaram's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes David Bredt (Insider), Abraham Ceesay (CEO), Cheryl Gault (COO), James Healy (Director), Troy Ignelzi (CFO), Krishnaswamy Yeleswaram (Insider), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, Rapport Therapeutics insiders bought shares 3 times. They purchased a total of 19,400 shares worth more than $240,350.00. During the last year, insiders at the sold shares 20 times. They sold a total of 193,991 shares worth more than $4,933,186.08. The most recent insider tranaction occured on January, 20th when CEO Abraham Ceesay sold 5,833 shares worth more than $152,357.96. Insiders at Rapport Therapeutics own 13.6% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 1/20/2026.

Krishnaswamy Yeleswaram Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/31/2025	Sell	2,840	$30.05	$85,342.00	296,991

Krishnaswamy Yeleswaram Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $27.09

$26.16

$27.60

50 Day Range

MA: $28.46

$25.55

$31.90

2 Week Range

Now: $27.09

$6.43

$42.27

Volume

301,708 shs

Average Volume

345,516 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63